Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most
immunomodulatory strategies focus on enhancing T cell responses, but there has been a …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …

Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

Introduction We previously reported an interim analysis of the DADI (dasatinib
discontinuation) trial. The results showed that 48% of patients with chronic myeloid leukemia …

Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal
chromosomal translocation between chromosomes 9 and 22 [t (9; 22)], producing the Bcr …

There is currently no biomarker that reliably predicts treatment‐free remission (TFR) in
chronic myeloid leukaemia (CML). We characterised effector and suppressor immune …